Q. A 65-year-old woman with a history of atrial fibrillation (AF) presents for a follow-up visit. She has been taking warfarin for the past year. Her international normalized ratio (INR) has been within the therapeutic range, and she has not experienced any bleeding events. However, she expresses concern about the inconvenience of regular INR monitoring and dietary restrictions associated with warfarin. She asks if any newer medications may be suitable for her. Which of the following responses is more appropriate in addressing her concerns?